SPCS1 and cervical cancer: Targeting this pathway—such as with inhibitors disrupting TvAP65-SPCS1 interaction or neutralizing TvAP65 antibodies—may prevent or reduce co-infection by T. vaginalis and HPV, thereby lowering cervical cancer risk.